Bibliotecas PUC-SP - Busca Integrada

Objective Supervised Machine Learning-Based Classification and Inference of Biological Neuronal Networks

por Michael Taynnan Barros, Harun Siljak, Peter Mullen, Constantinos Papadias, Jari Hyttinen, Nicola Marchetti
Publicado en Molecules (2022-09-01)

A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death.

por Oliver J Read, Jennifer Bré, Ying Zhang, Peter Mullen, Mustafa Elshani, David J Harrison
Publicado en PLoS ONE (2025-01-01)

A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death

por Oliver J. Read, Jennifer Bré, Ying Zhang, Peter Mullen, Mustafa Elshani, David J. Harrison
Publicado en PLoS ONE (2025-01-01)

Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapy.

por Dana Faratian, Andrew H Sims, Peter Mullen, Charlene Kay, Inhwa Um, Simon P Langdon, David J Harrison
Publicado en PLoS ONE (2011-01-01)

Kidney tumoroid characterisation by spatial mass spectrometry with same-section multiplex immunofluorescence uncovers tumour microenvironment lipid signatures associated with aggre...

por Hazem Abdullah, Greice M. Zickuhr, In Hwa Um, Alexander Laird, Peter Mullen, David J. Harrison, Alison L. Dickson
Publicado en npj Imaging (2025-09-01)

Diversity of matriptase expression level and function in breast cancer.

por Arkadiusz Welman, Duncan Sproul, Peter Mullen, Morwenna Muir, Andrew R Kinnaird, David J Harrison, Dana Faratian, Valerie G Brunton, Margaret C Frame
Publicado en PLoS ONE (2012-01-01)

Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine

por Dillum Patel, Alison L. Dickson, Greice M. Zickuhr, In Hwa Um, Oliver J. Read, Clarissa M. Czekster, Peter Mullen, David J. Harrison, Jennifer Bré
Publicado en Translational Oncology (2024-12-01)

Collateral-resistance to estrogen and HER-activated growth is associated with modified AKT, ERα, and cell-cycle signaling in a breast cancer model

por Kate M. Moore, Vera Cerqueira, Kenneth G. MacLeod, Peter Mullen, Richard L. Hayward, Simon Green, David J. Harrison, David A. Cameron, Simon P. Langdon
Publicado en Exploration of Targeted Anti-tumor Therapy (2022-02-01)

Overcoming intratumoural heterogeneity for reproducible molecular risk stratification: a case study in advanced kidney cancer

por Alexander L. R. Lubbock, Grant D. Stewart, Fiach C. O’Mahony, Alexander Laird, Peter Mullen, Marie O’Donnell, Thomas Powles, David J. Harrison, Ian M. Overton
Publicado en BMC Medicine (2017-06-01)